Daniel B. Kim-Shapiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniel B. Kim-Shapiro has a total of 296 co-authors. Here are the top co-authors by number of shared publications:
Mark T. Gladwin
University of Maryland School of Medicine
19 shared publicationsSwati Basu
Department of Physics, Wake Forest University, Winston-Salem, USA
17 shared publicationsS. Bruce King
Department of Molecular Medicine and Translational Science, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA; Department of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA
16 shared publications- Mark T. Gladwin
Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
15 shared publications - Jesús Tejero
Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, 15260, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
9 shared publications - Ivan Azarov
Wake Forest University
8 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Elsevier in Redox Biochemistry and Chemistry
- Vol. 17
Ascorbate-catalyzed reductive nitrosylation of ferric myoglobin
- 17 August 2026
- Published by Elsevier in Redox Biochemistry and Chemistry
- Vol. 17
Open AccessAscorbate-catalyzed reductive nitrosylation of ferric myoglobin
- 2 July 2026
- Published by Springer Nature
- p. 15-21
Hemoglobin-Based Oxygen Carrier: Impact Upon Vasoactive Effectors and Blood Flow
- 2 July 2026
- Published by Springer Nature
- p. 15-21
Hemoglobin-Based Oxygen Carrier: Impact Upon Vasoactive Effectors and Blood Flow
- Open Access
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Ascorbate-Catalyzed Reductive Nitrosylation of Ferric Myoglobin
Myoglobin plays a key role in oxygen storage and delivery through oxygen binding and release from the ferrous (Fe +2) heme. However, when the heme is oxidized to its ferric (Fe +3) form it can no longer bind oxygen and further oxidation leads to lipid peroxidation which can lead to a variety of pathological consequences. The ferric heme can be reduced to the ferrous form by nitric oxide (NO) through classical reductive nitrosylation but this reaction, where a second NO molecule binds to the reduced heme to form iron nitrosyl myoglobin, is very slow and inefficient. We have recently demonstrated that glutathione (and other thiols) can catalyze reductive nitrosylation of free ferric heme (hemin) when solubilized in albumin or red blood cell ghosts and the NO-ferroheme has potent NO signaling properties. In this work we show this catalysis is also viable in myoglobin and that ascorbate is a better catalyst than glutathione with reductive nitrosylation occurring 1000 times faster in the presence of ascorbate compared to its absence under some conditions. Our data support a mechanism involving ascorbate-mediated heme reduction forming an ascorbyl radical. Only one NO molecule and 0.5 ascorbate molecules are needed to convert one ferric myoglobin to one nitrosyl myoglobin molecule. Addition of NO and ascorbate are shown to be more protective against lipid peroxidation due to myoglobin oxidation by hydrogen peroxide than either ascorbate or NO alone. This reaction has potential application in meat preservation and treatment of ischemic reperfusion injury, various myopathies, and rhabdomyolysis.
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAscorbate-Catalyzed Reductive Nitrosylation of Ferric Myoglobin
Myoglobin plays a key role in oxygen storage and delivery through oxygen binding and release from the ferrous (Fe +2) heme. However, when the heme is oxidized to its ferric (Fe +3) form it can no longer bind oxygen and further oxidation leads to lipid peroxidation which can lead to a variety of pathological consequences. The ferric heme can be reduced to the ferrous form by nitric oxide (NO) through classical reductive nitrosylation but this reaction, where a second NO molecule binds to the reduced heme to form iron nitrosyl myoglobin, is very slow and inefficient. We have recently demonstrated that glutathione (and other thiols) can catalyze reductive nitrosylation of free ferric heme (hemin) when solubilized in albumin or red blood cell ghosts and the NO-ferroheme has potent NO signaling properties. In this work we show this catalysis is also viable in myoglobin and that ascorbate is a better catalyst than glutathione with reductive nitrosylation occurring 1000 times faster in the presence of ascorbate compared to its absence under some conditions. Our data support a mechanism involving ascorbate-mediated heme reduction forming an ascorbyl radical. Only one NO molecule and 0.5 ascorbate molecules are needed to convert one ferric myoglobin to one nitrosyl myoglobin molecule. Addition of NO and ascorbate are shown to be more protective against lipid peroxidation due to myoglobin oxidation by hydrogen peroxide than either ascorbate or NO alone. This reaction has potential application in meat preservation and treatment of ischemic reperfusion injury, various myopathies, and rhabdomyolysis.
- Open Access
- 18 February 2026
- Published by Elsevier in SSRN Electronic Journal
Sensitive and specific methodology for detection of labile NO-ferroheme complexes in vitro and in blood
Nitric oxide (NO) is formed via the oxidation of L-arginine in a reaction catalyzed by the NO synthase enzymes or via reduction of inorganic nitrite (NO2–) by deoxygenated hemoproteins and molybdopterin enzymes. We have recently demonstrated that NO can form a stable, labile ferrous heme-nitrosyl complex (NO-ferroheme) that protects NO from scavenging reactions in blood and has potent vasodilatory and platelet signaling activity. To enable future in vivo and in vitro studies establishing physiological NO-ferroheme formation, transport, and signaling, accurate and sensitive detection methods specifically for NO-ferroheme in biological milieu must be developed and validated. NO-heme complexes can be oxidized to release NO into the gas-phase for ozone-based chemiluminescence detection, which has been used for detection of iron-nitrosylated hemoglobin. In the current studies, we extend classical assays such as acidic potassium triiodide – with and without acidified sulfanilamide (AS) pre-treatment to eliminate NO2– and mercury(II) chloride (HgCl2) pretreatment to eliminate S-nitrosothiols – to detect and quantify NO-ferroheme, S-nitrosothiols, and nitrite. We also developed a new potassium ferricyanide/cyanide-based assay for sensitive and specific NO-ferroheme detection. All assays are sensitive and specific for NO-ferroheme to concentrations as low as 5 nM, with validated detection in buffer, plasma, whole blood and in vivo studies in mice. Additionally, we detect and quantify in vivo plasma NO-ferroheme formation and levels in mice after treatment with lipopolysaccharide (LPS), modeling pathological sepsis. These studies validate highly sensitive and specific assays for NO-ferroheme quantification and for the first time demonstrate plasma NO-ferroheme formation in vivo in a sepsis model.
- 18 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSensitive and specific methodology for detection of labile NO-ferroheme complexes in vitro and in blood
Nitric oxide (NO) is formed via the oxidation of L-arginine in a reaction catalyzed by the NO synthase enzymes or via reduction of inorganic nitrite (NO2–) by deoxygenated hemoproteins and molybdopterin enzymes. We have recently demonstrated that NO can form a stable, labile ferrous heme-nitrosyl complex (NO-ferroheme) that protects NO from scavenging reactions in blood and has potent vasodilatory and platelet signaling activity. To enable future in vivo and in vitro studies establishing physiological NO-ferroheme formation, transport, and signaling, accurate and sensitive detection methods specifically for NO-ferroheme in biological milieu must be developed and validated. NO-heme complexes can be oxidized to release NO into the gas-phase for ozone-based chemiluminescence detection, which has been used for detection of iron-nitrosylated hemoglobin. In the current studies, we extend classical assays such as acidic potassium triiodide – with and without acidified sulfanilamide (AS) pre-treatment to eliminate NO2– and mercury(II) chloride (HgCl2) pretreatment to eliminate S-nitrosothiols – to detect and quantify NO-ferroheme, S-nitrosothiols, and nitrite. We also developed a new potassium ferricyanide/cyanide-based assay for sensitive and specific NO-ferroheme detection. All assays are sensitive and specific for NO-ferroheme to concentrations as low as 5 nM, with validated detection in buffer, plasma, whole blood and in vivo studies in mice. Additionally, we detect and quantify in vivo plasma NO-ferroheme formation and levels in mice after treatment with lipopolysaccharide (LPS), modeling pathological sepsis. These studies validate highly sensitive and specific assays for NO-ferroheme quantification and for the first time demonstrate plasma NO-ferroheme formation in vivo in a sepsis model.
- Open Access
- 5 September 2025
- Published by Elsevier in Nitric Oxide
- Vol. 159, 40-50
Role of hydrogen sulfide in catalyzing the formation of NO-ferroheme
- 5 September 2025
- Published by Elsevier in Nitric Oxide
- Vol. 159, 40-50
Open AccessRole of hydrogen sulfide in catalyzing the formation of NO-ferroheme
- Open Access
- 5 August 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (32)
Engineering a highly selective, hemoprotein-based scavenger as a carbon monoxide poisoning antidote with no hypertensive effect
Carbon monoxide (CO) poisoning causes 50,000 to 100,000 emergency department visits and ~1,500 deaths in the United States annually. Current treatments are limited to supplemental and/or hyperbaric oxygen to accelerate CO elimination. Even with oxygen therapy, nearly half of CO poisoning survivors suffer long-term cardiac and neurocognitive deficits related to slow CO clearance, highlighting a need for point of care antidotal therapies. Given the natural interaction between CO and ferrous heme, we hypothesized that the hemoprotein RcoM, a transcriptional regulator of microbial CO metabolism, would make an ideal platform for CO-selective scavenging from endogenous hemoproteins. We engineered an RcoM truncate (RcoM-HBD-CCC) that exhibits high CO affinity ( K a,CO = 2.8 × 10 10 M −1 ), remarkable selectivity for CO over oxygen ( K a,O2 = 1.4 × 10 5 M −1 ; K a,CO / K a,O2 = 1.9 × 10 5 ), thermal stability (T m = 72 °C), and slow autoxidation rate ( k ox = 1.1 h −1 ). In a murine model of acute CO poisoning, infused RcoM-HBD-CCC accelerated CO clearance from hemoglobin in red blood cells (RBCs) and was rapidly excreted in urine. Moreover, infused RcoM-HBD-CCC elicited minimal hypertension in mice compared to infused globins (hemoglobin, myoglobin, and neuroglobin), attributed to a comparatively limited reactivity toward nitric oxide (NO) via dioxygenation [ k NOD (RcoM) = 6 to 8 × 10 6 M −1 s −1 vs k NOD (Hb) = 6 to 8 × 10 7 M −1 s −1 ]. These data suggest that RcoM-HBD-CCC is a safe, selective, and efficacious CO scavenger. By limiting hypertension through minimal NO scavenging, RcoM-HBD-CCC improves end-organ adverse effects compared with other hemoprotein-based therapeutics.
- 5 August 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (32)
Open AccessEngineering a highly selective, hemoprotein-based scavenger as a carbon monoxide poisoning antidote with no hypertensive effect
Carbon monoxide (CO) poisoning causes 50,000 to 100,000 emergency department visits and ~1,500 deaths in the United States annually. Current treatments are limited to supplemental and/or hyperbaric oxygen to accelerate CO elimination. Even with oxygen therapy, nearly half of CO poisoning survivors suffer long-term cardiac and neurocognitive deficits related to slow CO clearance, highlighting a need for point of care antidotal therapies. Given the natural interaction between CO and ferrous heme, we hypothesized that the hemoprotein RcoM, a transcriptional regulator of microbial CO metabolism, would make an ideal platform for CO-selective scavenging from endogenous hemoproteins. We engineered an RcoM truncate (RcoM-HBD-CCC) that exhibits high CO affinity ( K a,CO = 2.8 × 10 10 M −1 ), remarkable selectivity for CO over oxygen ( K a,O2 = 1.4 × 10 5 M −1 ; K a,CO / K a,O2 = 1.9 × 10 5 ), thermal stability (T m = 72 °C), and slow autoxidation rate ( k ox = 1.1 h −1 ). In a murine model of acute CO poisoning, infused RcoM-HBD-CCC accelerated CO clearance from hemoglobin in red blood cells (RBCs) and was rapidly excreted in urine. Moreover, infused RcoM-HBD-CCC elicited minimal hypertension in mice compared to infused globins (hemoglobin, myoglobin, and neuroglobin), attributed to a comparatively limited reactivity toward nitric oxide (NO) via dioxygenation [ k NOD (RcoM) = 6 to 8 × 10 6 M −1 s −1 vs k NOD (Hb) = 6 to 8 × 10 7 M −1 s −1 ]. These data suggest that RcoM-HBD-CCC is a safe, selective, and efficacious CO scavenger. By limiting hypertension through minimal NO scavenging, RcoM-HBD-CCC improves end-organ adverse effects compared with other hemoprotein-based therapeutics.
- Open Access
Dietary nitrate and nitrite protect against doxorubicin-induced cardiac fibrosis and oxidative protein damage in tumor-bearing mice
Anthracycline-induced cardiotoxicity remains a major limitation in cancer therapy, affecting long-term cardiovascular health in survivors. Dietary nitrate supplementation has shown cardioprotective effects in preclinical models of doxorubicin (Dox)-induced and ischemia-reperfusion injury. In this study, we evaluated the protective effects of nitrate and nitrite (NOx) supplementation in a syngeneic, tumor-bearing mouse model undergoing Dox chemotherapy (N=5 per group). NOx supplementation significantly reduced cardiac fibrosis and levels of 4-hydroxynonenal-modified proteins, a marker of oxidative stress. Tumor sizes varied, but most regressed by the final Dox dose. Importantly, NOx did not compromise the anti-tumor efficacy of Dox nor did it promote pulmonary metastasis. These findings support the potential clinical use of dietary nitrate and nitrite as adjuncts to Dox treatment to mitigate cardiotoxicity without impairing anti-cancer outcomes. Graphical
Open AccessDietary nitrate and nitrite protect against doxorubicin-induced cardiac fibrosis and oxidative protein damage in tumor-bearing mice
Anthracycline-induced cardiotoxicity remains a major limitation in cancer therapy, affecting long-term cardiovascular health in survivors. Dietary nitrate supplementation has shown cardioprotective effects in preclinical models of doxorubicin (Dox)-induced and ischemia-reperfusion injury. In this study, we evaluated the protective effects of nitrate and nitrite (NOx) supplementation in a syngeneic, tumor-bearing mouse model undergoing Dox chemotherapy (N=5 per group). NOx supplementation significantly reduced cardiac fibrosis and levels of 4-hydroxynonenal-modified proteins, a marker of oxidative stress. Tumor sizes varied, but most regressed by the final Dox dose. Importantly, NOx did not compromise the anti-tumor efficacy of Dox nor did it promote pulmonary metastasis. These findings support the potential clinical use of dietary nitrate and nitrite as adjuncts to Dox treatment to mitigate cardiotoxicity without impairing anti-cancer outcomes. Graphical
- 1 November 2024
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 102 (11) , 634-647
The acute effects of dietary nitrate supplementation on postmenopausal endothelial resistance to ischemia reperfusion injury: a randomized, placebo-controlled, double blind, crossover clinical trial
Postmenopausal cardiovascular health is a critical determinant of longevity. Consumption of beetroot juice (BR) and other nitrate-rich foods is a safe, effective non-pharmaceutical intervention to increase systemic bioavailability of the vasoprotective molecule, nitric oxide, through the exogenous nitrate (NO3 −)–nitrite (NO2 −)–nitric oxide (NO) pathway. We hypothesized that a single dose of nitrate-rich beetroot juice (BRnitrate 600 mg NO3 −/140 mL, BRplacebo ∼ 0 mg/140 mL) would improve resting endothelial function and resistance to ischemia–reperfusion (IR) injury to a greater extent in early-postmenopausal (1–6 years following their final menstrual period (FMP), n = 12) compared to late-postmenopausal (6+ years after FMP, n = 12) women. Analyses with general linear models revealed a significant ( p < 0.05) time*treatment interaction effect for brachial artery adjusted flow-mediated dilation (FMD). Pairwise comparisons revealed that adjusted FMD was significantly lower following IR-injury in comparison to all other time points with BRplacebo (early FMD 2.51 ± 1.18%, late FMD 1.30 ± 1.10, p < 0.001) and was lower than post-IR with BRnitrate (early FMD 3.84 ± 1.21%, late FMD 3.21 ± 1.13%, p = 0.014). A single dose of BRnitrate significantly increased resting macrovascular function in the late postmenopausal group only ( p = 0.005). Considering the postmenopausal stage-dependent variations in endothelial responsiveness to dietary nitrate, we predict differing mechanisms underpin macrovascular protection against IR injury.
- 1 November 2024
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 102 (11) , 634-647
The acute effects of dietary nitrate supplementation on postmenopausal endothelial resistance to ischemia reperfusion injury: a randomized, placebo-controlled, double blind, crossover clinical trial
Postmenopausal cardiovascular health is a critical determinant of longevity. Consumption of beetroot juice (BR) and other nitrate-rich foods is a safe, effective non-pharmaceutical intervention to increase systemic bioavailability of the vasoprotective molecule, nitric oxide, through the exogenous nitrate (NO3 −)–nitrite (NO2 −)–nitric oxide (NO) pathway. We hypothesized that a single dose of nitrate-rich beetroot juice (BRnitrate 600 mg NO3 −/140 mL, BRplacebo ∼ 0 mg/140 mL) would improve resting endothelial function and resistance to ischemia–reperfusion (IR) injury to a greater extent in early-postmenopausal (1–6 years following their final menstrual period (FMP), n = 12) compared to late-postmenopausal (6+ years after FMP, n = 12) women. Analyses with general linear models revealed a significant ( p < 0.05) time*treatment interaction effect for brachial artery adjusted flow-mediated dilation (FMD). Pairwise comparisons revealed that adjusted FMD was significantly lower following IR-injury in comparison to all other time points with BRplacebo (early FMD 2.51 ± 1.18%, late FMD 1.30 ± 1.10, p < 0.001) and was lower than post-IR with BRnitrate (early FMD 3.84 ± 1.21%, late FMD 3.21 ± 1.13%, p = 0.014). A single dose of BRnitrate significantly increased resting macrovascular function in the late postmenopausal group only ( p = 0.005). Considering the postmenopausal stage-dependent variations in endothelial responsiveness to dietary nitrate, we predict differing mechanisms underpin macrovascular protection against IR injury.
- 9 October 2024
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 225, 316-322
Nitrosyl hemoglobin formation from nitrite in normal and sickle blood
- 9 October 2024
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 225, 316-322
Nitrosyl hemoglobin formation from nitrite in normal and sickle blood
- Open Access
- 10 June 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1359671
Seven-day dietary nitrate supplementation clinically significantly improves basal macrovascular function in postmenopausal women: a randomized, placebo-controlled, double-blind, crossover clinical trial
Introduction: Cardiovascular disease (CVD) is the leading cause of death in women, with increased risk following menopause. Dietary intake of beetroot juice and other plant-based nitrate-rich foods is a promising non-pharmacological strategy for increasing systemic nitric oxide and improving endothelial function in elderly populations. The purpose of this randomized, placebo-controlled, double-blind, crossover clinical trial was to determine the effects of short-term dietary nitrate (NO3−) supplementation, in the form of beetroot juice, on resting macrovascular endothelial function and endothelial resistance to whole-arm ischemia–reperfusion (IR) injury in postmenopausal women at two distinct stages of menopause.Methods: Early-postmenopausal [1–6 years following their final menstrual period (FMP), n = 12] and late-postmenopausal (6+ years FMP, n = 12) women consumed nitrate-rich (400 mg NO3−/70 mL) and nitrate-depleted beetroot juice (approximately 40 mg NO3−/70 mL, placebo) daily for 7 days. Brachial artery flow-mediated dilation (FMD) was measured pre-supplementation (Day 0), and approximately 24 h after the last beetroot juice (BR) dose (Day 8, post-7-day BR). Consequently, FMD was measured immediately post-IR injury and 15 min later (recovery).Results: Results of the linear mixed-effects model revealed a significantly greater increase in resting FMD with 7 days of BRnitrate compared to BRplacebo (mean difference of 2.21, 95% CI [0.082, 4.34], p = 0.042); however, neither treatment blunted the decline in post-IR injury FMD in either postmenopausal group. Our results suggest that 7-day BRnitrate-mediated endothelial protection is lost within the 24-h period following the final dose of BRnitrate.Conclusion: Our findings demonstrate that nitrate-mediated postmenopausal endothelial protection is dependent on the timing of supplementation in relation to IR injury and chronobiological variations in dietary nitrate metabolism.Clinical trial registration: https://classic.clinicaltrials.gov/ct2/show/NCT03644472
- 10 June 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1359671
Open AccessSeven-day dietary nitrate supplementation clinically significantly improves basal macrovascular function in postmenopausal women: a randomized, placebo-controlled, double-blind, crossover clinical trial
Introduction: Cardiovascular disease (CVD) is the leading cause of death in women, with increased risk following menopause. Dietary intake of beetroot juice and other plant-based nitrate-rich foods is a promising non-pharmacological strategy for increasing systemic nitric oxide and improving endothelial function in elderly populations. The purpose of this randomized, placebo-controlled, double-blind, crossover clinical trial was to determine the effects of short-term dietary nitrate (NO3−) supplementation, in the form of beetroot juice, on resting macrovascular endothelial function and endothelial resistance to whole-arm ischemia–reperfusion (IR) injury in postmenopausal women at two distinct stages of menopause.Methods: Early-postmenopausal [1–6 years following their final menstrual period (FMP), n = 12] and late-postmenopausal (6+ years FMP, n = 12) women consumed nitrate-rich (400 mg NO3−/70 mL) and nitrate-depleted beetroot juice (approximately 40 mg NO3−/70 mL, placebo) daily for 7 days. Brachial artery flow-mediated dilation (FMD) was measured pre-supplementation (Day 0), and approximately 24 h after the last beetroot juice (BR) dose (Day 8, post-7-day BR). Consequently, FMD was measured immediately post-IR injury and 15 min later (recovery).Results: Results of the linear mixed-effects model revealed a significantly greater increase in resting FMD with 7 days of BRnitrate compared to BRplacebo (mean difference of 2.21, 95% CI [0.082, 4.34], p = 0.042); however, neither treatment blunted the decline in post-IR injury FMD in either postmenopausal group. Our results suggest that 7-day BRnitrate-mediated endothelial protection is lost within the 24-h period following the final dose of BRnitrate.Conclusion: Our findings demonstrate that nitrate-mediated postmenopausal endothelial protection is dependent on the timing of supplementation in relation to IR injury and chronobiological variations in dietary nitrate metabolism.Clinical trial registration: https://classic.clinicaltrials.gov/ct2/show/NCT03644472